Glovista Investments LLC Purchases 119,420 Shares of SPDR S&P Biotech ETF (XBI)

Glovista Investments LLC increased its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2,729.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 123,796 shares of the exchange traded fund’s stock after buying an additional 119,420 shares during the quarter. SPDR S&P Biotech ETF accounts for approximately 2.0% of Glovista Investments LLC’s investment portfolio, making the stock its 14th largest position. Glovista Investments LLC owned approximately 0.25% of SPDR S&P Biotech ETF worth $10,709,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in XBI. Quantitative Investment Management LLC boosted its holdings in SPDR S&P Biotech ETF by 642.3% in the second quarter. Quantitative Investment Management LLC now owns 1,451,998 shares of the exchange traded fund’s stock valued at $112,065,000 after acquiring an additional 1,256,398 shares during the last quarter. Assetmark Inc. boosted its holdings in SPDR S&P Biotech ETF by 59.9% in the third quarter. Assetmark Inc. now owns 1,239,051 shares of the exchange traded fund’s stock valued at $107,265,000 after acquiring an additional 464,246 shares during the last quarter. SG Americas Securities LLC boosted its holdings in SPDR S&P Biotech ETF by 162.8% in the third quarter. SG Americas Securities LLC now owns 303,622 shares of the exchange traded fund’s stock valued at $26,285,000 after acquiring an additional 188,106 shares during the last quarter. NF Trinity Capital Hong Kong Ltd bought a new stake in SPDR S&P Biotech ETF in the third quarter valued at approximately $10,302,000. Finally, Tavio Capital LLC bought a new stake in SPDR S&P Biotech ETF in the third quarter valued at approximately $10,027,000.

Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) traded up $2.11 during mid-day trading on Thursday, reaching $82.06. The company had a trading volume of 472,681 shares. SPDR S&P Biotech ETF has a 1-year low of $58.66 and a 1-year high of $88.98.

ILLEGAL ACTIVITY WARNING: This article was first published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/12/07/glovista-investments-llc-purchases-119420-shares-of-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply